المؤلفون: Jocelyn Fotso Soh, Katie Bodenstein, Oriana Hoi Yun Yu, Outi Linnaranta, Suzane Renaud, Artin Mahdanian, Chien-Lin Su, Istvan Mucsi, Benoit Mulsant, Nathan Herrmann, Tarek Rajji, Serge Beaulieu, Harmehr Sekhon, Soham Rej

المصدر: BMC Endocrine Disorders, Vol 22, Iss 1, Pp 1-7 (2022)

مصطلحات موضوعية: Hypercalcemia, Hyperparathyroidism, Atorvastatin, lithium use, Calcium, Bipolar disorder, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Abstract Background Although lithium is considered the gold-standard treatment for bipolar disorder (BD), it is associated with a variety of major endocrine and metabolic side effects, including parathyroid hormone (PTH) dependent hypercalcemia. Aside from surgery and medication discontinuation, there are limited treatments for hypercalcemia. This paper will assess data from a randomized controlled trial (RCT). Methods This is a secondary analysis of an RCT that explored the effects of atorvastatin (n = 27) versus placebo (n = 33) on lithium-induced nephrogenic diabetes insipidus (NDI) in patients with BD and major depressive disorder (MDD) using lithium (n = 60), over a 12-week period. This secondary analysis will explore serum calcium levels and thyroid stimulating hormone (TSH) measured at baseline, week 4, and week 12. Results At 12-weeks follow-up while adjusting results for baseline, linear regression analyses found that corrected serum calcium levels were significantly lower in the treatment group (mean (M) = 2.30 mmol/L, standard deviation (SD) = 0.07) compared to the placebo group (M = 2.33 mmol/L, SD = 0.07) (β = − 0.03 (95% C.I.; − 0.0662, − 0.0035), p = 0.03) for lithium users. There were no significant changes in TSH. Conclusion In lithium users with relatively normal calcium levels, receiving atorvastatin was associated with a decrease in serum calcium levels. Although exciting, this is a preliminary finding that needs further investigation with hypercalcemic patients. Future RCTs could examine whether atorvastatin can treat PTH dependent hypercalcemia due to lithium and other causes.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1472-6823Test

الوصول الحر: https://doaj.org/article/fe458ac4af3a4007814cf0589be6f408Test

المؤلفون: Magnus Bein, Oriana Hoi Yun Yu, Sonia Marzia Grandi, Francesca Y. E. Frati, Ihab Kandil, Kristian B. Filion

المصدر: BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-17 (2021)

مصطلحات موضوعية: Subclinical hypothyroidism, Levothyroxine, Pregnancy outcomes, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Abstract Background Levothyroxine replacement therapy may decrease the risk of adverse pregnancy outcomes among women with subclinical hypothyroidism (SCH). The aim of this study is to conduct a systematic review and meta-analysis to examine the risk of adverse pregnancy, perinatal, and early childhood outcomes among women with SCH treated with levothyroxine. Methods A systematic literature search was conducted using Ovid-Medline, Ovid-EMBASE, Pubmed (non-Medline), Ebsco-CINAHL Plus with full text and Cochrane Library databases. Randomized controlled studies (RCTs) and observational studies examining the association between treatment of SCH during pregnancy and our outcomes of interest were included. Studies that compared levothyroxine treatment versus no treatment were eligible for inclusion. Data from included studies were extracted and quality assessment was performed by two independent reviewers. Results Seven RCTs and six observational studies met our inclusion criteria. A total of 7342 individuals were included in these studies. RCTs demonstrated several sources of bias, with lack of blinding of the participants or research personnel; only one study was fully blinded. In the observational studies, there was moderate to serious risk of bias due to lack of adjustment for certain confounding variables, participant selection, and selective reporting of results. Pooled analyses showed decreased risk of pregnancy loss (RR: 0.79; 95% CI: 0.67 to 0.93) and neonatal death (RR: 0.35; 95% CI: 0.17 to 0.72) associated with levothyroxine treatment during pregnancy among women with SCH. There were no associations between levothyroxine treatment and outcomes during labour and delivery, or cognitive status in children at 3 or 5 years of age. Conclusion Treatment of SCH with levothyroxine during pregnancy is associated with decreased risks of pregnancy loss and neonatal death. Given the paucity of available data and heterogeneity of included studies, additional studies are needed to address the benefits of levothyroxine use among pregnant women with SCH.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1472-6823Test

الوصول الحر: https://doaj.org/article/387d59ca25e54e8bb52ab8f2d4562826Test

المؤلفون: Juan Gómez-Izquierdo, Kristian B. Filion, Jean-Franҫois Boivin, Laurent Azoulay, Michael Pollak, Oriana Hoi Yun Yu

المصدر: BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-10 (2020)

مصطلحات موضوعية: Subclinical hypothyroidism, Cancer, Systematic review, Mortality, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Abstract Background Thyroid hormone has been shown to be involved in carcinogenesis via its effects on cell proliferation pathways. The objective of this study is to determine the association between subclinical hypothyroidism (SCH) and the risk of incident cancer and cancer mortality via systematic review. Methods A systematic search was performed on Medline and Pubmed to identify relevant studies. Randomized controlled trials, and observational studies assessing SCH or its treatment and the risk of incident cancer or cancer mortality were identified. Results A total of 7 cohort and 2 case-control studies met our inclusion criteria. In general, these studies were of medium to good quality. Overall, studies revealed no association between SCH and breast and prostate cancer. One study found that untreated SCH may be associated with an increased risk of colorectal cancer (adjusted odds ratio [OR]: 1.16; 95% confidence interval [CI]: 1.08–1.24). One study showed an increased risk in thyroid cancer incidence (adjusted OR: 3.38; 95% CI: 2.05–5.59) associated with elevation of a thyroid stimulating hormone (TSH) of > 1.64mIU/L. Two studies found an increase in cancer mortality among patients with SCH compared to euthyroid individuals; in contrast one study found no association between subclinical hypothyroidism and cancer mortality among aging men. Conclusion The number of studies examining thyroid dysfunction and cancer risk and mortality is limited. Future studies assessing the association between thyroid dysfunction and cancer risk and mortality are needed, which will further address the need to treat subclinical hypothyroidism.

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12902-020-00566-9Test; https://doaj.org/toc/1472-6823Test

الوصول الحر: https://doaj.org/article/ccb6910ce72e4dae9bb5f621dde0ae49Test

المؤلفون: Lan Deng, Wusiman Aibibula, Zahra Talat, Kristian B. Filion, Shaun Eintracht, Kaberi Dasgupta, Vicky Tagalakis, Agnieszka Majdan, Oriana Hoi Yun Yu

المصدر: Endocrinology, Diabetes & Metabolism, Vol 4, Iss 3, Pp n/a-n/a (2021)

مصطلحات موضوعية: adverse events, cohort study, glycaemic target, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Abstract Introduction Hyperglycaemia is common during hospitalization; glycaemic targets in non‐critical care settings have not been well studied. We assessed associations between inpatient glycaemic control and adverse events. Methods We conducted a retrospective cohort study on non‐critically ill medical patients hospitalized in a tertiary care hospital between 2015 and 2018. Mean glycaemia during the first four days of hospitalization was categorized as 4.0–7.0 mmol/L, 7.1–10.0 mmol/L and >10.0 mmol/L. The primary outcome was a composite of adverse events including mortality, infections, acute kidney injury, thromboembolic and cardiovascular events. The secondary outcome was hypoglycaemia, defined as any glycaemia 10.0 mmol/L (adjusted OR: 0.98, 95% CI: 0.75–1.28) and the occurrence of adverse events, compared to a glycaemia of 7.1–10.0 mmol/L. Glycaemia of >10.0 mmol/L was associated with an increased risk of hypoglycaemia (adjusted hazard ratio [HR]: 1.72, 95% CI: 1.21–2.45). Hypoglycaemia was associated with adverse events (adjusted OR 1.85, 95% CI 1.31–2.60). Conclusions Neither glycaemia of 4.0–7.0 mmol/L nor glycaemia of >10.0mmol/L during non‐critical care hospitalization was associated with increased adverse events. Glycaemia of >10.0 mmol/L was associated with increased hypoglycaemia, likely due to aggressive glucose lowering. These findings highlight the need for further studies to discern optimal inpatient glycaemic targets.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2398-9238Test

الوصول الحر: https://doaj.org/article/d136cfead2ee4887b92ae25a71b794bdTest

المؤلفون: Kimya Hassani-Ardakani, Mark L. Lipman, Denny Laporta, Oriana Hoi Yun Yu

المصدر: Case Reports in Endocrinology, Vol 2021 (2021)

مصطلحات موضوعية: Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2090-6501Test; https://doaj.org/toc/2090-651XTest

الوصول الحر: https://doaj.org/article/06898bf1d81a49db95aa549a1a69e503Test

المؤلفون: Kimya Hassani-Ardakania, Mark L. Lipman, Denny Laporta, Oriana Hoi Yun Yu

المصدر: Case Reports in Endocrinology, Vol 2019 (2019)

مصطلحات موضوعية: Diseases of the endocrine glands. Clinical endocrinology, RC648-665

الوصف: Background. Sodium glucose cotransport (SGLT)-2 inhibitors are the newest class of antihyperglycemic agents used as second- or third-line treatment in the management of type 2 diabetes. Although the use of SGLT-2 inhibitors has not been shown to cause nephrotoxicity, there have been case reports of SGLT-2 inhibitor use being associated with acute kidney injury. Case Presentation. A 72-year-old woman with a history of type 2 diabetes and no known chronic renal insufficiency presented to the emergency room with a 3-day history of nausea, vomiting, and increased somnolence. She was found to have potassium level of 7.4 (normal: 3.5-5.5) mmol/L and a markedly elevated creatinine level at 1154 (normal: 45-95) μmol/L. Imaging of the abdomen and pelvis did not reveal any findings of obstruction. Urine microscopy showed many granular casts. In the absence of other causes for her clinical presentation, the patient was diagnosed with acute kidney injury secondary to ischemic acute tubular necrosis, with canagliflozin use likely an important contributing factor. Conclusions. Physicians should inform patients to stop the use of SGLT-2 inhibitors when patients are unable to maintain hydration or during acute illness. Use of SGLT-2 inhibitors in managing type 2 diabetes should be done with caution among more vulnerable populations, including individuals with cognitive impairment and the elderly.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2090-6501Test; https://doaj.org/toc/2090-651XTest

الوصول الحر: https://doaj.org/article/cda304473e4443fe8c5be466ae316057Test

المؤلفون: Fatema Alkhamees (14286490), Oriana Hoi Yun Yu (14286493), Mianbo Wang (838584), Marie Hudson (289434)

مصطلحات موضوعية: Rheumatology and Arthritis, Scleroderma, gender, occupation, outcomes, gender variables

الوصف: Supplemental material, sj-pdf-1-jso-10.1177_23971983221143599 for Occupation as a gendered-role and outcome in systemic sclerosis by Fatema Alkhamees, Oriana Hoi Yun Yu, Mianbo Wang and Marie Hudson in Journal of Scleroderma and Related Disorders

العلاقة: https://figshare.com/articles/journal_contribution/sj-pdf-1-jso-10_1177_23971983221143599_Supplemental_material_for_Occupation_as_a_gendered-role_and_outcome_in_systemic_sclerosis/21761149Test

الإتاحة: https://doi.org/10.25384/sage.21761149.v1Test

المؤلفون: Oriana Hoi Yun Yu, Samy Suissa

المصدر: Diabetes Care. 46:904-912

مصطلحات موضوعية: Advanced and Specialized Nursing, Endocrinology, Diabetes and Metabolism, Internal Medicine

الوصف: The quest to repurpose metformin, an antidiabetes drug, as an agent for cancer prevention and treatment, which began in 2005 with an observational study that reported a reduction in cancer incidence among metformin users, generated extensive experimental, observational, and clinical research. Experimental studies revealed that metformin has anticancer effects via various pathways, potentially inhibiting cancer cell proliferation. Concurrently, multiple nonrandomized observational studies reported remarkable reductions in cancer incidence and outcomes with metformin use. However, these studies were shown, in 2012, to be affected by time-related biases, such as immortal time bias, which tend to greatly exaggerate the benefit of a drug. The observational studies that avoided these biases did not find an association. Subsequently, the randomized trials of metformin for the treatment of type 2 diabetes and as adjuvant therapy for the treatment of various cancers, advanced or metastatic, did not find reductions in cancer incidence or outcomes. Most recently, the largest phase 3 randomized trial of metformin as adjuvant therapy for breast cancer, which enrolled 3,649 women with a 5-year follow-up, found no benefit for disease-free survival or overall survival with metformin. This major failure of observational real-world evidence studies in correctly assessing the effects of metformin on cancer incidence and outcomes was caused by preventable biases which, surprisingly, are still prominent in 2022. Rigorous approaches for observational studies that emulate randomized trials, such as the incident and prevalent new-user designs along with propensity scores, avoid these biases and can provide more accurate real-world evidence for the repurposing of drugs such as metformin.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ed496ab04dcbfba4a1edc1ce6deca143Test
https://doi.org/10.2337/dci22-0047Test

المؤلفون: Magnus Bein (10208171), Oriana Hoi Yun Yu (9119816), Sonia Marzia Grandi (10208174), Francesca Y. E. Frati (10208177), Ihab Kandil (10208180), Kristian B. Filion (10208183)

مصطلحات موضوعية: Medicine, Cell Biology, Biotechnology, Cancer, Science Policy, Subclinical hypothyroidism, Levothyroxine, Pregnancy outcomes

الوصف: Additional file 1.

العلاقة: https://figshare.com/articles/journal_contribution/Additional_file_1_of_Levothyroxine_and_the_risk_of_adverse_pregnancy_outcomes_in_women_with_subclinical_hypothyroidism_a_systematic_review_and_meta-analysis/14130758Test

الإتاحة: https://doi.org/10.6084/m9.figshare.14130758.v1Test

المؤلفون: Thi Xuan Dai, Cao, Christopher, Filliter, François, Montastruc, Oriana Hoi Yun, Yu, Emma, Fergusson, Soham, Rej, Laurent, Azoulay, Christel, Renoux

المصدر: Journal of Affective Disorders. 318:231-237

مصطلحات موضوعية: Serotonin Plasma Membrane Transport Proteins, Serotonin, Adolescent, Citalopram, Paroxetine, Psychiatry and Mental health, Clinical Psychology, Diabetes Mellitus, Type 2, Fluvoxamine, Fluoxetine, Sertraline, Humans, Selective Serotonin Reuptake Inhibitors, Antipsychotic Agents

الوصف: Selective serotonin reuptake inhibitors (SSRIs) have been associated with type 2 diabetes mellitus (T2DM) in youths, possibly via 5-HTUsing the UK Clinical Practice Research Datalink, we assembled a cohort of patients aged 5-24, newly prescribed a strong-affinity SSRI (citalopram, escitalopram, fluoxetine) or weak affinity (paroxetine, sertraline, fluvoxamine) between 1990 and 2019. We controlled for confounding using standardized mortality ratio weighting, estimated from calendar time-specific propensity scores. We used weighted Cox proportional hazards models to estimate hazard ratios (HRs) of incident T2DM with 95 % confidence intervals (CIs).The cohort included 347,368 new users of strong-affinity SSRIs and 131,359 of weak-affinity SSRIs. Strong-affinity SSRIs were not associated with an increased T2DM risk compared with weak-affinity SSRIs (incidence rate 2.8 vs 2.7 per 1000 person-years; HR 1.03, 95 % CI 0.85-1.25). T2DM risk did not vary with duration of use, age or sex. However, the HR was numerically higher in youths with normal or low weight (HR 1.30, 95 % CI 0.85-1.98) and with prior antipsychotic use (HR 1.62, 95 % CI 0.83-3.18).Median duration of SSRI use, in line with real-world SSRI prescribing, was relatively short.T2DM risk did not differ between strong- and weak-affinity SSRIs, providing reassurance for clinicians when choosing between SSRIs in youths.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f670ca347ec751514f1c5eb7054a72Test
https://doi.org/10.1016/j.jad.2022.08.094Test